Mitral Valve Repair — Cost, Top Hospitals & Success Rates | MyMedicPlus

Mitral valve repair is cardiac surgery to restore normal function of the mitral valve — the two-leaflet valve between the left atrium and left ventricle — without removing and replacing it with a prosthetic substitute. It is now the preferred surgical treatment for most forms of mitral valve regurgitation (MR), and at expert centres it achieves repair in over 95% of cases.

The mitral valve is a complex structure consisting of the anterior and posterior leaflets, the mitral annulus (fibrous ring supporting the leaflets), the chordae tendineae (tendon-like cords connecting leaflets to papillary muscles), and two papillary muscles arising from the left ventricular wall. Competent valve function requires all these components to work in coordinated fashion.

Mitral regurgitation occurs when the valve fails to close completely during systole, allowing blood to flow backwards into the left atrium. Over time, this volume overload dilates the left ventricle and atrium, impairs cardiac function, causes atrial fibrillation, and leads to pulmonary hypertension if untreated.

Repair — reconstructing the diseased valve using the patient's own tissue — is preferred over replacement for several fundamental reasons: it preserves the native subvalvular apparatus (chordae and papillary muscles), which is critical for maintaining left ventricular geometry and systolic function; it avoids the need for lifelong anticoagulation (required for mechanical valves); it eliminates prosthesis-related complications such as thromboembolism, structural valve deterioration, and endocarditis risk; and it confers better long-term survival than replacement. Multiple observational studies and the current AHA/ACC and ESC guidelines reflect a strong Class I recommendation for repair over replacement when repair is feasible.

When surgical repair is not possible or carries prohibitive risk, transcatheter approaches including the MitraClip (TEER — transcatheter edge-to-edge repair) provide a catheter-based alternative.

The Carpentier functional classification (1983) organises mitral regurgitation into three types based on leaflet motion, providing a systematic framework that guides repair technique selection:

• Type I — Normal leaflet motion with annular dilation: The leaflets are structurally normal but the annulus has dilated, preventing complete leaflet coaptation. The primary cause is dilated cardiomyopathy (functional/secondary MR). Treatment is ring annuloplasty to reduce the annular diameter and restore coaptation. This is also seen in paravalvular leak from infective endocarditis of the annulus.
• Type II — Excessive leaflet motion (prolapse): One or both leaflets prolapse above the mitral annular plane during systole due to chordal elongation or rupture, or leaflet excess (billowing). This is the most common type in the Western world — 60–70% of surgical mitral repairs. Causes include myxomatous degeneration (Barlow disease, with extensive leaflet redundancy and prolapse) and fibroelastic deficiency (FED, with focal chordal rupture and segmental prolapse, commoner in older patients). Surgical repair includes leaflet resection, neochordae implantation, and ring annuloplasty.
• Type IIIa — Restricted leaflet motion in systole and diastole (rheumatic): Leaflet thickening, calcification, commissural fusion, and chordal shortening from rheumatic fever restrict leaflet opening and closing. Repair is technically demanding and less durable than for degenerative disease; replacement is more frequently required.
• Type IIIb — Restricted leaflet motion in systole only (ischaemic/functional): Left ventricular dilation and papillary muscle displacement tether the mitral leaflets apically, preventing normal coaptation. This secondary (functional) MR is a consequence of left ventricular disease, most commonly ischaemic cardiomyopathy or idiopathic dilated cardiomyopathy. Surgery addresses the annular dilation component; the underlying LV disease requires separate treatment. MitraClip/TEER has an important role here.

Additional indications include:

• Infective endocarditis: Selected cases with vegetation, leaflet perforation, or chordal involvement can be repaired (debridement, pericardial patch, neochordae) rather than replaced, reducing prosthesis-related infection risk
• Congenital mitral valve anomalies: Cleft mitral valve (AV canal defect), parachute mitral valve, and mitral arcade in paediatric patients are repaired with suturing of cleft leaflets and subvalvular reconstruction

Patient selection for mitral valve repair is guided by disease severity, symptom status, left ventricular function, and anatomical suitability for repair:

Surgical Mitral Valve Repair — Indications

• Class I (Recommended): Symptomatic severe MR (breathlessness, reduced exercise tolerance, orthopnea) in patients with LVEF ≥30%. Surgery is clearly indicated to relieve symptoms and prevent irreversible LV damage.
• Class IIa (Reasonable): Asymptomatic severe MR with either: (a) LVEF 30–60% (evidence of early LV impairment), (b) left ventricular end-systolic diameter (LVESD) ≥40 mm (LV dilation despite normal EF), (c) new-onset atrial fibrillation, or (d) pulmonary hypertension (SPAP >50 mmHg at rest). Repair at experienced centres (repair rate >95%) justifies early intervention before LV dysfunction develops.
• Class IIa (Reasonable) — Asymptomatic severe MR with high repair probability: When performed at a Heart Valve Centre of Excellence where durable repair can be achieved with <1% mortality, early elective repair in asymptomatic patients preserves long-term LV function and reduces AF risk.

Anatomical Suitability for Repair

• Posterior leaflet prolapse/flail (most commonly P2 scallop) is the most surgically straightforward repair — resection and reconstruction achieves excellent and durable results in experienced hands
• Anterior leaflet prolapse requires more complex techniques (neochordae, edge-to-edge suture) and has slightly lower repair rates and durability than posterior prolapse, though expert centres still achieve >90% repair
• Bileaflet prolapse (Barlow disease) is technically challenging but achievable with comprehensive repair strategies
• Heavily calcified annulus or leaflets, commissural calcification, or rheumatic disease with extensive subvalvular involvement reduces repair durability and may favour replacement at non-specialist centres

MitraClip / TEER — Transcatheter Eligibility

• Symptomatic moderate-to-severe or severe secondary (functional) MR in heart failure patients with LVEF 20–50%
• Patients remaining symptomatic (NYHA II–IVa) despite optimal guideline-directed medical therapy (maximally tolerated beta-blocker, ACE inhibitor/ARNi, MRA, diuretics)
• Prohibitive or high surgical risk (STS-PROM ≥8% or Heart Team assessment of unfavourable risk)
• Mitral anatomy meeting COAPT trial inclusion criteria on transesophageal echocardiography (TEE): adequate coaptation length, acceptable leaflet mobility, no severe calcification of the grasping zone)

The surgical techniques for mitral valve repair were systematically codified by Alain Carpentier (Paris) in the 1970s and 1980s and remain the foundation of contemporary practice:

Posterior Leaflet Resection: Quadrangular and Triangular Resection

For posterior leaflet prolapse due to chordal elongation or rupture — the most common finding in degenerative MR — the prolapsing segment is excised using quadrangular resection (removal of a rectangular portion of the posterior leaflet containing the flail segment). When the resected height is large relative to annular width, a sliding plasty (slide advancement) is performed: the posterior annulus is plicated centrally and the remaining leaflet halves are slid towards each other and sutured to reconstruct a competent leaflet. Triangular resection is used for smaller, discrete prolapsing segments and avoids the leaflet height reduction of quadrangular resection. Ring annuloplasty is always performed concurrently.

Chordal Reconstruction: ePTFE Neochordae (Gore-Tex)

Expanded polytetrafluoroethylene (ePTFE, Gore-Tex CV-5) sutures are used to create artificial chordae — neochordae — that replace ruptured or elongated native chords. The neochord is attached to the papillary muscle head at its base and to the prolapsing leaflet margin. Chordal length is calibrated to restore the leaflet tip to the plane of the mitral annulus. This technique is preferred for anterior leaflet prolapse and for bileaflet prolapse in Barlow disease, preserving maximum leaflet tissue. Long-term durability of ePTFE neochordae at 10 years equals or exceeds leaflet resection in experienced hands.

Papillary muscle relocation (suturing displaced papillary muscles towards the ventricular septum) is used for ischaemic MR type IIIb to relieve tethering of the posterior leaflet.

Alfieri Edge-to-Edge Repair

A single suture approximates the central portions of the anterior and posterior mitral leaflets, creating a double-orifice valve. Originally described by Ottavio Alfieri (Milan), this technique is a rescue procedure for residual MR after primary repair, or a primary technique for central bileaflet prolapse when complex reconstruction is not feasible. It is also the surgical basis for the MitraClip transcatheter device. Durability is inferior to anatomical reconstruction techniques when used as a sole procedure without ring annuloplasty.

Ring Annuloplasty: The Essential Component of Every Repair

A prosthetic ring is sutured around the mitral annulus to remodel annular geometry, reduce excessive annular diameter, reinforce the repair, and prevent future annular dilation. Ring selection depends on pathology:

• Flexible partial rings (Carpentier-Edwards Classic Annuloplasty Ring): for Type IIIa rheumatic disease, where preservation of annular flexibility is desired
• Semi-rigid complete rings (Carpentier-Edwards Physio II, Medtronic Profile 3D): for degenerative MR. These rings reinforce the entire annulus with three-dimensional geometry that respects the natural saddle shape of the mitral annulus, reducing leaflet stress. The Physio II has a flexible posterior segment and rigid anterior bar — the most widely used ring design for degenerative disease.
• Rigid undersized rings (Carpentier-McCarthy-Adams IMR ETlogix): for functional/ischaemic MR (Type IIIb) where aggressive annular reduction is the primary goal. However, restrictive annuloplasty alone for ischaemic MR has a 30% recurrence rate at 2 years (MitraClip is increasingly preferred for this indication after the COAPT trial).

MitraClip / Transcatheter Edge-to-Edge Repair (TEER)

The MitraClip (Abbott) replicates the Alfieri edge-to-edge technique without surgery. Via transseptal puncture through the femoral vein, the device is steered under real-time 3D transesophageal echocardiography to the mitral valve. The clip grasps both leaflets at the site of regurgitation and approximates them, immediately reducing MR. Multiple clips can be deployed at different leaflet positions. The newer PASCAL Precision device (Edwards Lifesciences) offers a wider paddle design for better leaflet grasping and is CE-marked and FDA-approved.

The COAPT trial (2018, NEJM): 614 heart failure patients with secondary MR on maximally tolerated GDMT were randomised to MitraClip plus GDMT vs GDMT alone. At 2 years, MitraClip reduced the rate of hospitalisation for heart failure by 47% (relative risk), reduced all-cause mortality by 38%, and reduced the rate of death from any cause within 2 years by 29%. This was a landmark trial establishing TEER as standard of care for secondary functional MR in heart failure patients meeting the COAPT criteria.

The superiority of mitral valve repair over replacement is one of the most robust findings in cardiac surgery, supported by decades of outcome data:

• Survival advantage: Multiple large observational studies and meta-analyses demonstrate significantly better long-term survival after mitral valve repair versus replacement. A landmark analysis from the Mayo Clinic (>1,000 patients) showed 10-year survival of approximately 70% after repair versus 55% after replacement for degenerative MR — a 15-percentage-point survival advantage largely attributable to preserved left ventricular function.
• Preserved left ventricular function: Preservation of the subvalvular apparatus (chordae and papillary muscles) during repair maintains the geometric relationship between the mitral valve and the left ventricular wall that is essential for efficient LV contraction. Removal of the subvalvular apparatus during replacement — even with modern surgical techniques — reduces LV ejection fraction by an average of 8–10 percentage points that is never recovered. This explains the survival gap.
• No lifelong anticoagulation required: Mechanical prosthetic valves require lifelong anticoagulation with warfarin (INR 2.5–3.5) to prevent valve thrombosis and thromboembolic stroke. This carries an annual bleeding risk of 1–2% and requires frequent INR monitoring and dietary restrictions. After repair, anticoagulation is not required in patients with sinus rhythm. Even bioprosthetic valve recipients require anticoagulation for 3 months, and the valve will degenerate within 10–15 years, requiring reoperation.
• Excellent durability: For degenerative posterior leaflet prolapse (the most common indication), freedom from reoperation at 10 years exceeds 90% at experienced centres and approaches 85% at 20 years. Durability is lower for anterior leaflet prolapse and significantly lower for rheumatic disease (75% at 10 years). Experience and technique matter enormously — centres performing fewer than 25 repairs per year have significantly lower repair rates and durability.
• Lower risk of prosthetic valve endocarditis: All prosthetic valves (mechanical, bioprosthetic, and transcatheter) carry a risk of endocarditis of 0.5–1.0% per year. A repaired native valve has significantly lower long-term endocarditis risk than any prosthesis.
• Quality of life: Freedom from anticoagulation, the absence of mechanical valve clicking, and the knowledge that the patient's own valve is intact all contribute to substantially better quality of life after repair versus replacement.

Mitral valve repair carries both the general risks of any cardiac surgical procedure and specific risks related to the repair technique:

Operative Risks

• In-hospital mortality: For isolated mitral valve repair in elective setting, operative mortality at experienced centres is below 1% (0.3–0.8%). Combined procedures (MV repair + CABG, MV repair + AF ablation) carry higher risk (1.5–3%).
• Stroke: Risk of perioperative stroke is 1–2% for isolated valve surgery, related to cardiopulmonary bypass, aortic manipulation, and postoperative atrial fibrillation.
• New atrial fibrillation: Postoperative AF occurs in 25–40% of patients, typically within the first 3–5 days. Most episodes are transient and managed with rate control and anticoagulation; approximately 10–15% develop permanent AF.

Repair-Specific Complications

• Residual MR: Intraoperative transesophageal echocardiography (TEE) assesses repair result after coming off bypass. If residual MR is moderate or greater, the repair is revised or conversion to replacement is undertaken. Residual MR after surgery (1–2+ on a scale of 0–4) is associated with earlier reoperation. Target after successful repair is 0–1+ residual MR.
• Systolic anterior motion (SAM): A potentially serious complication specific to mitral repair, in which the anterior mitral leaflet is displaced anteriorly into the left ventricular outflow tract (LVOT) during systole, causing dynamic LVOT obstruction. SAM risk is increased with small hearts, high posterior leaflet height, and posterior displacement of the coaptation point. Risk is reduced by avoiding excessive posterior leaflet tissue, using asymmetric ring placement, and intraoperative manoeuvres (volume loading, reducing inotropes, phenylephrine). Severe SAM requires repair revision or conversion to replacement.
• Ring dehiscence: Partial or complete separation of the prosthetic ring from the annulus, usually from technical error or infective endocarditis. Requires surgical revision.
• Late repair failure (reoperation): Approximately 5–10% of degenerative MR repairs require reoperation within 10 years for recurrent MR from repair failure. Risk factors include anterior leaflet involvement, Barlow disease, and rheumatic aetiology.

MitraClip-Specific Risks

• Transseptal puncture complications (pericardial effusion, haematoma): <1%
• Partial clip detachment requiring repeat procedure: 3–5%
• Residual MR requiring surgical intervention: rare (<2%) in experienced hands

Recovery monitoring after mitral valve repair involves echocardiographic surveillance, medication management, endocarditis prevention, and lifestyle guidance:

In-Hospital Recovery

• Hospital stay is typically 5–7 days after uncomplicated surgical mitral valve repair. ICU stay is 1–2 days post-operatively.
• Chest tubes are removed by day 2–3; epicardial pacing wires are removed at 4–5 days if no conduction abnormality is present.
• Sternal precautions (for median sternotomy): no lifting over 5 kg for 6 weeks, no driving for 6 weeks. Mini-thoracotomy patients have no sternal restrictions and may drive at 4 weeks.

Anticoagulation After Repair

• For patients in sinus rhythm after repair: aspirin 75–100 mg daily for 3 months is generally prescribed, after which anticoagulation is not required. Long-term anticoagulation is not needed after biological repair.
• For patients with postoperative atrial fibrillation: warfarin (INR 2.0–3.0) or direct oral anticoagulant (DOAC — apixaban, rivaroxaban) is initiated. If sinus rhythm is restored and maintained, anticoagulation can be reassessed at 3–6 months based on CHA2DS2-VASc score.
• Patients with mechanical prosthetic rings (rare): warfarin with INR target 2.5–3.5 indefinitely.

Echocardiographic Follow-Up Schedule

• Intraoperative TEE: Immediately after separation from cardiopulmonary bypass to assess repair result — this is the most important quality control step
• Pre-discharge TTE: Establishes the baseline post-repair MR grade and LV dimensions
• 1 month: TTE to confirm repair integrity and assess any structural changes
• 6 months: TTE — particularly important for patients with residual trace/mild MR post-repair
• Annually thereafter: Lifelong annual TTE is recommended for all patients with repaired mitral valves (AHA/ACC and ESC guideline recommendation)

Endocarditis Prophylaxis

All patients with prosthetic material implanted in the heart (prosthetic rings, neochordae) require antibiotic prophylaxis before invasive dental procedures: amoxicillin 2 g orally 30–60 minutes before the procedure (clindamycin 600 mg if penicillin-allergic). This recommendation persists lifelong per ESC 2023 and AHA 2021 endocarditis prevention guidelines.

Cardiac Rehabilitation and Return to Activity

Structured cardiac rehabilitation after valve surgery reduces rehospitalisation, improves functional capacity, and enhances quality of life. Patients are typically cleared for light exercise (walking) within 2–4 weeks, moderate exercise at 6–8 weeks, and full activity including sport at 12 weeks, subject to echocardiographic confirmation of repair integrity.

The cost of mitral valve repair varies substantially between countries, centre types, and surgical approaches:

Surgical Mitral Valve Repair

• United States: Total hospital cost (including prosthetic ring, surgeon and anaesthesiologist fees, and 5–7 day hospitalisation) ranges from USD $60,000–$120,000 for isolated mitral valve repair. Combined procedures (MV repair + MAZE + tricuspid repair) are correspondingly more expensive.
• India (top-tier cardiac centres): USD $6,000–$12,000 total, using equivalent-quality Carpentier-Edwards or Medtronic prosthetic rings and the same operative standards. Major centres including AIIMS Delhi, Fortis Escorts, and Apollo Hospitals perform high-volume mitral repair with outcomes comparable to Western series.
• Thailand / Singapore: USD $12,000–$25,000 at JCI-accredited hospitals.
• Germany / Netherlands: EUR 20,000–40,000 including hospitalisation.

MitraClip / TEER

• The MitraClip G4 device (Abbott) costs approximately USD $25,000–$30,000 per clip system. Most procedures use 1–3 clips. Total procedure cost in the US is USD $40,000–$75,000.
• In India: USD $12,000–$20,000 (device import costs dominate pricing).
• MitraClip is reimbursed by Medicare in the US for secondary MR meeting COAPT-like criteria. NHS England has commissioned TEER for appropriate patients in England as of 2021.

Centre Volume and Outcomes

The most important cost-quality determinant is centre volume. A Johns Hopkins analysis demonstrated that patients at high-volume mitral valve repair centres (>50 repairs/year) have significantly lower reoperation rates, lower mortality, and better long-term valve durability. The additional travel cost to reach a specialist centre is typically outweighed by the long-term savings of avoiding reoperation for repair failure.

When repair is not feasible or fails, several alternatives exist ranging from medical management to valve replacement and transcatheter options:

• Mitral valve replacement (MVR): When repair is technically not achievable or fails intraoperatively, the mitral valve is replaced with either a mechanical or bioprosthetic valve.
  Mechanical valves (St. Jude Medical Regent, On-X): excellent durability (30+ years) but require lifelong warfarin anticoagulation with its associated bleeding risk and lifestyle restrictions. Preferred in patients under 60–65 who will tolerate anticoagulation well.
  Bioprosthetic valves (Carpentier-Edwards Perimount Magna Ease, Medtronic Hancock): no anticoagulation required in sinus rhythm, but valve degeneration and reoperation typically required in 10–15 years (younger patients), or 15–20 years (patients over 70). Preferred in patients over 65–70 and those who cannot tolerate anticoagulation.
• Transcatheter mitral valve replacement (TMVR): An emerging catheter-based alternative to surgical MVR for patients with failed bioprosthetic valves (valve-in-valve TMVR — TIARA, Tendyne, Intrepid) or severely calcified native annuli. Currently investigational in most countries for native valve disease, though valve-in-valve procedures are increasingly adopted for degenerated bioprostheses.
• Medical management: For patients who are not surgical or transcatheter candidates, or who have asymptomatic mild-to-moderate MR below the intervention threshold, guideline-directed medical therapy manages symptoms and associated conditions: ACE inhibitors and ARBs for LV volume overload, beta-blockers for heart failure and rate control, diuretics for fluid retention, and anticoagulation if AF is present. Annual echocardiographic surveillance monitors disease progression.
• Balloon mitral valvuloplasty (Inoue technique): For rheumatic mitral stenosis (not regurgitation) with suitable valve morphology (Wilkins score ≤8), percutaneous balloon mitral commissurotomy (PBMC) is the treatment of choice — particularly in young patients in developing countries where rheumatic disease is prevalent. A single balloon catheter is inflated at the mitral orifice, splitting the fused commissures and enlarging the valve area. Results are excellent for suitable anatomy and defer or avoid the need for surgery.
• Watchful waiting with surveillance: Asymptomatic patients with moderate MR and normal LV dimensions and function are managed conservatively with echocardiographic surveillance every 6–12 months and risk factor optimisation. Surgery is deferred until Class I or Class IIa intervention thresholds are met.